Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Vaccines Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Vaccine

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $516.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition August 10, 2020


            Acquisition of Pfenex is expected to contribute a range of strategic benefits to Ligand like access to a proprietary, protein expression technology, utilized in various commercial and development-stage biopharmaceutical programs. Versatile operating business and among others.